Although CAR-T therapies currentlyaccount for a small fraction of EU healthcare expenditures, projected clinicalexpansion implies a substantial future budget impact. This underscores the need for innovation in manufacturing, logistics, and cost-efficient delivery toenable sustainable access. The EASYGEN consortium is strategically positioned to support such innovation by standardizing CAR-T processes, reducingper-patient costs, and facilitating scalable access across oncology andautoimmune indications.currently account for a small fraction of EU healthcare expenditures, projected clinical expansion